- Home
- MXCT
MXCT
MaxCyte Inc.
as 07-26-2024 4:00pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 474.6M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 602.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.45 - $5.54 | Next Earning Date: | 08-06-2024 |
| Revenue: | $44,053,700 | Revenue Growth: | 6.80% |
| Revenue Growth (this year): | -10.26% | Revenue Growth (next year): | 26.66% |
Stock Insider Trading Activity of MaxCyte Inc. (MXCT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Johnston John Joseph | MXCT | Director | Jun 27 '24 | Sell | $3.99 | 10,000 | $39,900.00 | 141,950 | SEC Form 4 |
| Ross Thomas M. | MXCT | EVP, GLOBAL SALES | Jun 20 '24 | Sell | $4.09 | 33,333 | $136,465.30 | 25,000 | SEC Form 4 |
| Masoud Maher | MXCT | President and CEO | Jun 7 '24 | Buy | $4.90 | 70,443 | $345,241.14 | 100,000 | SEC Form 4 |
| Masoud Maher | MXCT | President and CEO | Jun 7 '24 | Buy | $4.87 | 29,557 | $143,824.36 | 29,557 | SEC Form 4 |
| Johnston John Joseph | MXCT | Director | Mar 26 '24 | Sell | $4.41 | 5,000 | $22,025.00 | 120,583 | SEC Form 4 |
| Johnston John Joseph | MXCT | Director | Feb 26 '24 | Sell | $4.60 | 5,000 | $23,005.00 | 120,583 | SEC Form 4 |
| Johnston John Joseph | MXCT | Director | Jan 26 '24 | Sell | $5.12 | 5,000 | $25,585.00 | 120,583 | SEC Form 4 |
| Johnston John Joseph | MXCT | Director | Dec 26 '23 | Sell | $4.53 | 5,000 | $22,650.00 | 120,583 | SEC Form 4 |
| Doerfler Douglas | MXCT | President and CEO | Dec 4 '23 | Sell | $5.01 | 25,008 | $125,290.08 | 333,197 | SEC Form 4 |
| Doerfler Douglas | MXCT | President and CEO | Dec 4 '23 | Sell | $5.17 | 99,442 | $514,115.14 | 333,197 | SEC Form 4 |
| Doerfler Douglas | MXCT | President and CEO | Nov 29 '23 | Sell | $5.00 | 5,350 | $26,750.00 | 333,197 | SEC Form 4 |
| Doerfler Douglas | MXCT | President and CEO | Nov 29 '23 | Sell | $5.00 | 20,200 | $101,000.00 | 333,197 | SEC Form 4 |
| Johnston John Joseph | MXCT | Director | Nov 27 '23 | Sell | $4.59 | 5,000 | $22,950.00 | 120,583 | SEC Form 4 |
| Johnston John Joseph | MXCT | Director | Nov 14 '23 | Sell | $3.71 | 10,000 | $37,100.00 | 120,583 | SEC Form 4 |
Latest MaxCyte Inc. News
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
GlobeNewswire
17 days ago
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
Simply Wall St.
a month ago
President of MaxCyte Maher Masoud Buys More Stock
Zacks
a month ago
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
Zacks
a month ago
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
GuruFocus.com
2 months ago
Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT)
MT Newswires
2 months ago
Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing
GlobeNewswire
2 months ago
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
Compare MXCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.